home / stock / nurpf / nurpf short
Short Information | Neuren Pharms Ltd Ord (OTCMKTS:NURPF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 4,300 |
Total Actual Volume | 10,223 |
Short Trends | |
---|---|
Cover Days | 3 |
Short Days | 17 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 215 |
Average Short Percentage | 81.77% |
Is there a NURPF Short Squeeze or Breakout about to happen?
See the NURPF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-01-2024 | $0 | $14.25 | $0 | $0 | 57 | 30 | 52.63% |
06-28-2024 | $14.25 | $14.25 | $14.25 | $14.25 | 100 | 100 | 100% |
06-26-2024 | $13.74 | $13.74 | $13.74 | $13.74 | 3,400 | 21 | 0.62% |
06-25-2024 | $13.15 | $12.87 | $13.15 | $12.87 | 800 | 100 | 12.5% |
06-11-2024 | $12.6 | $12.6 | $12.6 | $12.6 | 327 | 327 | 100% |
06-07-2024 | $0 | $14 | $0 | $0 | 33 | 33 | 100% |
05-22-2024 | $14 | $13.91 | $14 | $13.91 | 650 | 649 | 99.85% |
05-13-2024 | $12.684 | $12.684 | $12.684 | $12.684 | 100 | 100 | 100% |
04-25-2024 | $12.51 | $12.51 | $12.51 | $12.51 | 600 | 600 | 100% |
04-15-2024 | $12.66 | $12.53 | $12.66 | $12.53 | 1,000 | 500 | 50% |
03-26-2024 | $13.45 | $13.45 | $13.45 | $13.45 | 100 | 100 | 100% |
03-19-2024 | $13.405 | $13.405 | $13.405 | $13.405 | 100 | 100 | 100% |
03-07-2024 | $0 | $12.22 | $0 | $0 | 50 | 50 | 100% |
02-28-2024 | $12.5 | $12.5 | $12.5 | $12.5 | 320 | 320 | 100% |
02-26-2024 | $13.6 | $13.88 | $13.88 | $13.6 | 200 | 200 | 100% |
02-16-2024 | $13.35 | $12.99 | $13.35 | $12.775 | 1,730 | 430 | 24.86% |
01-31-2024 | $0 | $15.56 | $0 | $0 | 20 | 20 | 100% |
01-29-2024 | $0 | $15.56 | $0 | $0 | 20 | 20 | 100% |
01-26-2024 | $15.86 | $15.56 | $15.86 | $15.56 | 370 | 360 | 97.3% |
01-25-2024 | $15.65 | $15.65 | $15.65 | $15.65 | 246 | 240 | 97.56% |
News, Short Squeeze, Breakout and More Instantly...
Neuren Pharms Ltd Ord Company Name:
NURPF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult an...